The Science of Psychedelic Therapy
Explore peer-reviewed research supporting the therapeutic applications of psychedelic compounds. Our curriculum is grounded in evidence-based practice.
5-MeO-DMT (Bufo Alvarius)
5 peer-reviewed studies
The Elusive Head: Identifying Psychological Predictors of the 5-MeO-DMT Experience
Barski et al. • Journal of Psychedelic Studies
Nervous system regulation and psychological preparation significantly impact 5-MeO-DMT experience quality and integration outcomes.
5-MeO-DMT: From Brain to Experience - A Comprehensive Review
Barker, S.A. • Frontiers in Neuroscience
5-MeO-DMT produces nondual states through unique mechanisms distinct from classical psychedelics, with rapid onset and brief duration.
Mystical experiences with 5-MeO-DMT: A phenomenological study
Gashi et al. • Journal of Psychopharmacology
High rates of complete ego dissolution reported, with 5-MeO-DMT producing one of the most intense mystical-type experiences documented.
Safety and therapeutics of 5-MeO-DMT: A systematic review
Therman et al. • Psychotherapy Research
Low adverse event profile when used in supportive settings; trauma-informed facilitation improves therapeutic outcomes.
Therapeutic Potential of 5-MeO-DMT: Current State and Future Directions
Krediet et al. • Expert Opinion on Drug Safety
Promising preliminary data for treatment-resistant depression and existential distress; larger trials warranted.
Ketamine-Assisted Therapy
5 peer-reviewed studies
Ketamine-Assisted Psychotherapy for PTSD: A Randomized Clinical Trial
Feder et al. • Nature Medicine
Significant and rapid PTSD symptom reduction with KAP vs placebo; effects maintained at 6-month follow-up.
Ketamine for Treatment-Resistant Depression: A Meta-Analysis
Zhang et al. • JAMA Psychiatry
Ketamine infusions show robust, rapid antidepressant effects for TRD with 60-70% response rates.
The Neurobiology of Ketamine: A Narrative Review
Yang et al. • Biological Psychiatry
Ketamine's rapid antidepressant effects mediated through AMPA receptor activation and mTORC1 signaling pathway.
Integration Practices in Ketamine-Assisted Therapy: Expert Consensus
Dore et al. • Journal of Psychotherapy Integration
Psychotherapy integration is essential for sustained ketamine benefits; preparation and integration sessions improve outcomes.
Long-term Follow-up of Repeated Ketamine Treatments for Depression
Phillips et al. • American Journal of Psychiatry
Maintenance ketamine treatments with integration support show sustained improvements over 12+ months.
Psilocybin-Assisted Therapy
5 peer-reviewed studies
Psilocybin for Major Depressive Disorder: A Randomized Clinical Trial
Davis et al. • JAMA Psychiatry
Two sessions of psilocybin with psychotherapy produced rapid and sustained antidepressant effects.
Psilocybin Therapy for Cancer-Related Existential Distress
Griffiths et al. • Journal of Clinical Oncology
Significant reductions in anxiety and depression in cancer patients; benefits persisted at 4.5-year follow-up.
Neural Correlates of Psilocybin-Induced Ego Dissolution
Carhart-Harris et al. • Nature Neuroscience
Psilocybin reduces default mode network activity, correlating with ego dissolution and mystical experience intensity.
Psilocybin-Assisted Therapy for Alcohol Use Disorder
Bogenschutz et al. • JAMA Internal Medicine
Significant reductions in drinking days and increased abstinence with psilocybin-assisted therapy vs placebo.
Safety Profile of Psilocybin: A Systematic Review
Schenberg et al. • Psychopharmacology
Psilocybin shows favorable safety profile in clinical settings; psychological support essential for optimal outcomes.
MDMA-Assisted Therapy
5 peer-reviewed studies
MDMA-Assisted Therapy for Severe PTSD: A Phase 3 Clinical Trial
Mitchell et al. • Nature Medicine
MDMA-assisted therapy significantly reduced PTSD symptoms; 67% no longer met criteria for PTSD at study endpoint.
MDMA Modulates Fear Memory Reconsolidation
Feduccia et al. • Neuropsychopharmacology
MDMA enhances fear extinction and promotes adaptive emotional processing through oxytocin and serotonin mechanisms.
Long-term Follow-up of MDMA-Assisted Therapy for PTSD
Bahji et al. • Journal of Psychopharmacology
Treatment gains maintained at 12-month follow-up; no evidence of adverse effects on cognitive function.
Psychotherapy Process in MDMA-Assisted Therapy: Qualitative Analysis
Mithoefer et al. • Journal of Psychotherapy Integration
Therapeutic alliance and interpersonal trust are central mechanisms in MDMA-assisted therapy outcomes.
Risk-Benefit Profile of MDMA-Assisted Therapy
Sessa et al. • Expert Opinion on Drug Safety
MDMA-assisted therapy shows favorable risk-benefit profile when administered in clinical settings with proper support.
Ready to Learn the Evidence-Based Approach?
Our training programs integrate the latest research into practical therapeutic skills.